middle Dose

DRUG4 trials

Sponsors

The First Affiliated Hospital of Anhui Medical University, Shulan (Hangzhou) Hospital, Beijing Northland Biotech. Co., Ltd., West China Hospital

Conditions

Acute Myocardial InfarctionChronic hepatitis BHeterozygous Familial HypercholesterolemiaOvarian CancermRNA Vaccine

Early Phase 1

A Single-Center, Open-label, Single-Arm, Dose Escalation and Dose Extension Investigator-Initiated Study (IIT) to Evaluate the Safety, Efficacy and Pharmacokinetic of EPI-001 Injection for the Treatment of Heterozygous Familial Hypercholesterolemia (HeFH)

Active, not recruitingChiCTR2400081208

The First Affiliated Hospital of Anhui Medical UniversityHeterozygous Familial Hypercholesterolemia

Start: 2024-02-27Updated: 2024-03-04

A study on the safety, tolerance, pharmacokinetics and pharmacodynamics of EPI-003T injection in the treatment of chronic hepatitis B subjects who have been treated with nucleoside (acid) analogues

Active, not recruitingChiCTR2500110861

Shulan (Hangzhou) HospitalChronic hepatitis B

Start: 2025-10-22Updated: 2025-10-27

Phase 1

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

RecruitingNCT07724106

West China HospitalOvarian Cancer, mRNA Vaccine

Start: 2026-09-10End: 2028-05-01Target: 9Updated: 2026-09-09

Phase 2

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

CompletedNCT05485818

Beijing Northland Biotech. Co., Ltd.Acute Myocardial Infarction

Start: 2020-11-23End: 2021-11-18Updated: 2022-08-03